Wealthfront Advisers
RXRX icon

Wealthfront Advisers’s Recursion Pharmaceuticals RXRX Stock Holding History

Wealthfront Advisers’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.4K Buy
14,820
+2,610
+21% +$8.69K ﹤0.01% 1109
2026
Q1 		$37.5K Sell
12,210
-1,641
-12% -$6.34K ﹤0.01% 1069
2025
Q4 		$56.7K Buy
13,851
+2,265
+20% +$11.2K ﹤0.01% 1046
2025
Q3 		$56.5K Buy
+11,586
New +$60.8K ﹤0.01% 1001

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Wealthfront Advisers's RXRX Position: Q2 2026 in Review

Wealthfront Advisers increased its Recursion Pharmaceuticals (RXRX) stake by 21% in Q2 2026, buying an estimated $8.69K and bringing the position to 14,820 shares worth $54.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1109.

Wealthfront Advisers first reported a position in RXRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $56.7K in Q4 2025. 218 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Wealthfront Advisers held 14,820 shares of Recursion Pharmaceuticals worth $54.4K as of Q2 2026.
  • Wealthfront Advisers bought 2,610 Recursion Pharmaceuticals shares in Q2 2026, an estimated $8.69K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #1109 holding.
  • Wealthfront Advisers first reported a position in Recursion Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Wealthfront Advisers's Recursion Pharmaceuticals position peaked at $56.7K in Q4 2025.
  • 218 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.